Merck KGaA, Darmstadt, Germany
Frankfurter Straße 250
Darmstadt
64293
Germany
Tel: 49-6151-720
Fax: 49-6151-722000
Website: https://www.emdgroup.com/en
Email: service@emdgroup.com
538 articles with Merck KGaA, Darmstadt, Germany
-
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany
6/1/2021
Sutro Biopharma, Inc. announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.
-
Data from EMD Serono’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
5/19/2021
New analyses from pivotal BAVENCIO® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma
-
Merck KGaA, Darmstadt, Germany, Announces Changes in Operating Model for Healthcare Business Sector
5/18/2021
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced changes in its operating model for the Healthcare business sector.
-
MoonLake Immunotherapeutics in-licenses potentially best-in-class Tri-specific Nanobody®,[6] Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany, with goal of transforming treatment of inflammatory diseases driven by IL-17A and F
5/3/2021
MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced that it has in-licensed the Tri-specific Nanobody® Sonelokimab (M1095/ALX 0761) from Merck KGaA, Darmstadt, Germany.
-
EMD Serono Announces New Data Strengthening Evidence for Use of MAVENCLAD During the COVID-19 Pandemic
4/28/2021
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets,
-
EMD Serono Announces New Data Strengthening Evidence for Continued Safe and Effective MAVENCLAD® Use During the COVID-19 Pandemic
4/23/2021
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced a new analysis from the MAGNIFY-MS sub-study showing a specific immune repopulation pattern in patients with relapsing multiple sclerosis (RMS) treated with MAVENCLAD® (cladribine) tablets, which may contribute to their ability to fight infections and develop protective antibodies from vaccines.
-
Clinical Catch-Up: April 12-16
4/19/2021
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look. -
NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
4/13/2021
NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, announced the expansion of its clinical trial and supply agreement with Merck KGaA, Darmstadt, Germany to conduct a Phase I/IIa open-label, single-center trial evaluating the safety and anti-tumor activity of SNK01 (autologous natural killer cells) in combination with either gemcitabine/carboplatin
-
PRA’s remote patient monitoring platform selected by Merck KGaA, Darmstadt, Germany to work in combination with its human growth hormone treatment system
4/7/2021
PRA Health Sciences (NASDAQ: PRAH) announced today that Merck KGaA, Darmstadt, Germany, known in the United States as EMD Serono, selected PRA’s remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.
-
A research collaboration among UCLA investigators and Merck KGaA, has pointed to the drug as showing promise for COVID-19. It is also being touted for its unusually broad effect in treating a range of cancers.
-
Clinical Catch-Up: March 15-19
3/22/2021
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look. -
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here's a look.
-
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
3/16/2021
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer who have failed or are intolerant of first-line platinum-based chemotherapy.
-
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
-
Genome and Company signs second clinical trial collaboration and supply agreement (Phase 2) with Merck KGaA, Darmstadt, Germany and Pfizer for immuno-oncology microbiome study
3/9/2021
Genome and Company (KOSDAQ: 314130), a leading global microbiome anti-cancer drug development company, signed a second clinical trial collaboration and supply agreement (CTCSA) with Merck KGaA, Darmstadt, Germany and Pfizer Inc. with the aim of developing the world's first immuno-oncology microbiome therapeutic
-
Merck KGaA, Darmstadt, Germany moves the Silicon Valley Innovation Hub to San Jose's Intermolecular site
3/4/2021
Merck KGaA, Darmstadt, Germany, a leading science and technology company, has moved its Silicon Valley Innovation Hub team to San Jose's Intermolecular's 150,000 sqft facility, creating a unique space for innovation and collaboration at the intersection of life science, healthcare and electronic materials.
-
Merck KGaA is consolidating its Silicon Valley business/technology and materials innovations facilities under one 30,000-square-foot roof in San Jose, California, in an effort to boost their collaborative capacity for developing materials with biological applications.
-
Merck KGaA, Darmstadt, Germany, Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
3/1/2021
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
Debiopharm Grants a Worldwide Exclusive License to Merck KGaA, Darmstadt, Germany for the Development and Commercialization of Xevinapant
3/1/2021
Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care
-
Merck KGaA, Darmstadt, Germany plunked down €188 million (about $226 million) in upfront cash to acquire exclusive global development and commercialization rights to Debiopharm’s oral Inhibitor of Apoptosis Proteins (IAP) antagonist, xevinapant.